Condition
Stage III NSCLC clinical trials and research
As of November 12, 2026, Find a Trial lists 2 Stage III NSCLC clinical trials that are recruiting, at sites in 2 countries (most in France (1), Italy (1)). By phase: Phase 2 (2). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 2Clinical trials
- 2Countries
All recruiting trials (2)
-
Neoadjuvant chemo-immunotherapy for PD-L1–positive Stage III non-small cell lung cancer
This tests whether three cycles of combined chemotherapy and the immunotherapy drug tislelizumab given before local treatment help adults with Stage III PD-L1–positive non-small cell lung cancer who are past or current smokers and do not have EGFR/ALK/ROS1/RET driver alterations.
-
Adjuvant chemotherapy with optional cemiplimab plus short-course sequential radiotherapy for unfit or elderly patients with stage III non-small cell lung cancer
This tests whether adding the immunotherapy cemiplimab to carboplatin‑paclitaxel chemotherapy and sequential short-course radiotherapy helps unfit or elderly people with unresectable stage III non-small cell lung cancer.
Quick answers
How many Stage III NSCLC clinical trials are recruiting right now?
2, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 2 countries. The most sites are in France (1 trial), Italy (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 2: 2. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.